BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

VDDI Pharmaceuticals, Michigan 

Innovation Center
4717 Campus Drive
Kalamazoo  Michigan  49008  U.S.A.
Phone: N/A Fax:


SEARCH JOBS
Advances in synthetic chemistry and drug screening techniques have flooded the pharmaceutical industry with potential new drugs. At the same time, industry consolidation and financial pressures on R&D budgets have reduced the ability of biotech and pharmaceutical companies to develop early stage drugs. As a result of these market forces, large pharmaceutical companies have restricted their drug development activities to "blockbuster" drugs ($1 billion revenues) with proven efficacy. Promising early-stage drugs developed in emerging biotech and pharmaceutical companies, and university research laboratories are being shelved.

VDDI has been formed to capitalize on these opportunities. The Company will license attractive product development opportunities from academic institutions, biotech firms and pharmaceutical companies. VDDI will focus on pharmaceutical product opportunities where general proof-of-principle has already been established in pre-clinical or human testing, and where the products are novel and offer significant potential advantages to products currently in the market or in development. VDDI will pursue early-stage products qualifying for fast track approval, primarily in the areas of cancer, cardiovascular disease and infectious disease and develop the products through Phase II of the required regulatory approval processes. The developed products will be licensed to existing pharmaceutical companies for product marketing, thereby generating license fees and ongoing royalties for VDDI.

As its name suggests, VDDI utilizes a virtual business model. Virtual drug development entails: (i) a small core group of employees responsible for strategic management, regulatory strategy, and financial control, (ii) outsourcing all non-core business functions, including preclinical and clinical drug development, and (iii) electronic data capture and data submission to regulatory authorities. By adopting this model, VDDI believes it can reduce total drug development program costs by at least 25% and development times by up to 50%.

VDDI is led by Dr. Stephen Porter, a recognized authority in virtual drug development with over 20 years of experience in the pharmaceutical industry. The Company has established relationships with a network of world-class pharmaceutical development firms and consultants. VDDI has also assembled scientific advisory boards composed of internationally-recognized researchers for each of its target therapeutic markets.

Last Updated: 03-17-03


 Key Statistics


Email:
Ownership: Private

Web Site: VDDI Pharmaceuticals, Michigan
Employees:
Symbol: 
 



Industry
Pharmaceutical






 Company News
Currently No News Articles

//-->